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Two decades ago, the available treatment options were 
not eﬀ  ective for many persons with rheumatoid arthritis 
(RA) and other inﬂ  ammatory rheumatic diseases. At this 
time RA patients had a signiﬁ   cantly decreased life 
expectancy due to a relatively incontrolled inﬂ  ammatory 
activity of RA combined with an increased incidence of 
comorbidities and severe treatment-related side eﬀ  ects. 
After 5 years of disease duration, a considerable percen-
tage of patients became unemployed. Th  e available 
disease-modifying anti  rheu  matic drugs were able to slow 
disease progression, but they could not stop it. Th  is 
unsatisfying situation changed signiﬁ   cantly at the 
beginning of the 1990s, when treat  ment options for RA 
patients expanded to include TNF blockers. Th  ese 
blockers were shown to signiﬁ  cantly decrease not only 
the inﬂ  ammatory activity of RA, but also the radiographic 
progression. Th  is breakthrough in therapeutic options 
was fostered by the pioneering research of Prof. Sir 
Ravinder Maini and Prof. Sir Marc Feldman working at 
the Kennedy Institute in London, who introduced a 
chimeric monoclonal antibody against TNFα in the treat-
ment of RA patients.
Since these early clinical trials, TNF inhibitors have 
radically changed the entire therapeutic approach, not 
only for RA but also for ankylosing spondylitis (AS) and 
for psoriatic arthritis (PsA). While the focus once was 
symptom mitigation, rheumatologists now seek control 
of disease progression. Today, TNF inhibitors eﬀ  ectively 
suppress and control the inﬂ   ammation driving these 
diseases, and thereby prevent irreversible tissue damage 
and disability. Radiographic studies are showing that 
progressive joint damage can be halted under certain 
conditions in some patients. Th   ese conditions and patients 
are currently being elucidated. New frontiers include 
early diagnosis and referral; optimizing treatment 
regimens; identifying patients at risk of rapidly progres-
sing disease; and instituting early, rapid TNF blockade in 
these patients. Using combination therapy with TNF 
inhibitors and disease-modifying antirheumatic drugs – 
speciﬁ   cally methotrexate – at an early stage of RA, 
disease progression can be stopped or at least signiﬁ  -
cantly retarded.
Th   e four articles in this supplement present up-to-date 
information, current data, and the best thinking on anti-
TNF therapy in RA, AS, and PsA. Since research over the 
past decade revealed that these three disorders share an 
inﬂ   ammatory mechanism fueled especially by TNF, 
eﬀ  orts to produce viable TNF inhibitors have accelerated.
Josef S Smolen and Paul Emery, in their article ‘Inﬂ  ixi-
mab: 12 Years of Experience’, expound upon the record of 
eﬃ     cacy and safety amassed for this TNF inhibitor. 
Research on inﬂ   iximab, which began with the ﬁ  rst 
randomized controlled study in a rheumatic disease, 
stimulated most of the development of TNF neutralizing 
therapies. Th   e authors summarize the major trials in RA, 
AS, and PsA that contributed to this body of evidence.
In the second article, ‘Understanding Emerging Treat-
ment Paradigms in Rheumatoid Arthritis’, Ferdinand C 
Breedveld and Bernard Combe assert that most patients 
with RA are undertreated. Th  ey outline accumulating 
data showing that intensive treatment in the early stages 
of RA can slow or stop disease progression, and they 
describe alternatives to traditional step-up approaches 
and to sequential monotherapy with disease-modifying 
antirheumatic drugs.
Next, Georg Schett and colleagues focus on bone and 
cartilage injury in all three diseases, with an emphasis on 
key knowledge arising from TNF research and how it has 
paved the way for future advances. Th   eir article, ‘Struc-
tural Damage in Rheumatoid Arthritis, Psoriatic 
Arthritis, and Ankylosing Spondylitis: Traditional Views, 
Novel Insights Gained from TNF Blockade, and Concepts 
for the Future’, explores the diﬀ  erent pathologies as well 
as radiographic data for the interaction between inﬂ  am-
mation and structural progression.
Lastly, Paul P Tak and I discuss innovative approaches – 
with TNF inhibitors but also with other biologic agents – 
to inﬂ  ammatory arthritides, including new targets within 
the inﬂ  ammatory cascade, agents designed to aﬀ  ect asso-
ciated pathways, and improved management strategies 
involving early diagnosis and referral. In the article  © 2010 BioMed Central Ltd
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we explore the variable response to targeted therapy and 
consider how best to integrate these advanced therapies 
into daily practice.
Our goal with the present supplement is to provide a 
valuable, current resource from which additional dialog 
may spring. We all agree that optimal treatment, initiated 
sooner, may reduce costs and risks to patients, and 
therefore achieve our common ambition – to help the 
patient and to attain low disease activity or remission in 
persons with inﬂ  ammatory arthritis.
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